Associate Professor of Medicine, Indiana University
Hematology
Dr. Kathy D. Miller, MD
|
|
Give Review
Kathy Miller practices Hematology. She went to medical school at Indiana University School of Medicine. Indiana University School of Medicine has a rank of 45 in research and a 47 in primary care She over the years received 1 awards: "Indianapolis Monthly". Kathy Miller is also a published doctor. She has 100 publication published. The most recent publication is: Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. She is registered with Medicare and accepts Medicare payments.
Publications
- Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199.
- Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
- Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer.
- A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast Cancer: translational breast Cancer research consortium tr...
- Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.
- Diffuse intrinsic pontine glioma biopsy: A single institution experience.
- Comparison of younger and older breast Cancer survivors and age-matched controls on specific and overall quality of life domains.
- 55p * pet/ct imaging of 64cu-labelled her2 liposomal Doxorubicin (64cu-mm-302) quantifies variability of liposomal drug deLivery to diverse tumor lesions in her2-posit...
- Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive, Locally Advanced, or Metastatic Breast Ca...
- Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast Cancer participating in E5103.
- Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy.
- Synthesis of (Z)-2-((1H-indazol-3-yl)methylene)-6-[¹¹C]methoxy-7-(piperazin-1-ylmethyl)benzofuran-3(2H)-one as a new potential PET probe for imaging of the enzyme PIM1.
- A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast Cancer: Hoosier Oncology Group Study BRE06-109.
- Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estro...
- Survival in patients with metastatic recurrent breast Cancer after adjuvant chemotherapy: Little evidence of improvement over the past 30 years.
- Synthesis of 2,6-difluoro-N-(3-[(11)C]methoxy-1H-pyrazolo[3,4-b]pyridine-5-yl)-3-(propylsulfonamidio)benzamide as a new potential PET agent for imaging of B-Raf(V600E)...
- Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bev...
- Synthesis of radiolabeled protein disulfide isomerase (PDI) inhibitors as new potential PET agents for imaging of the enzyme PDI in neurological disorders and Cancer.
- Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment.
- Cognitive Appraisals, Coping and Depressive Symptoms in Breast Cancer Patients.
- Simple synthesis of carbon-11-labeled chromen-4-one derivatives as new potential PET agents for imaging of DNA-dependent protein kinase (DNA-PK) in Cancer.
- A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2 -Positive Metastatic Breast Cancer Who Were Previously Treated With...
- Predicting fear of breast Cancer recurrence and self-efficacy in survivors by age at diagnosis.
- Synthesis of 2-[11C]methoxy-3,17β-O,O-bis(sulfamoyl)estradiol as a new potential PET agent for imaging of steroid sulfatase (STS) in Cancers.
- Health-Related Quality of Life of African American Breast Cancer Survivors Compared With Healthy African American Women.
- Facile radiosynthesis of new carbon-11-labeled propanamide derivatives as selective androgen receptor modulator (SARM) radioligands for prostate Cancer imaging.
- Cytochrome P450 Polymorphisms and their Relationship with Premature Ovarian Failure in Premenopausal Women with Breast Cancer Receiving Doxorubicin and Cyclophosphamide.
- Synthesis of [(11)C]PBR06 and [(18)F]PBR06 as agents for positron emission tomographic (PET) imaging of the translocator protein (TSPO).
- Synthesis and preliminary in vitro biological evaluation of new carbon-11-labeled celecoxib derivatives as candidate PET tracers for imaging of COX-2 expression in can...
- Breast Cancer in a wife: how husbands cope and how well it works.
- Radiosynthesis of [(11)C]Vandetanib and [(11)C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in Cancer.
- Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast Cancer.
- Synthesis of carbon-11-labeled casimiroin analogues as new potential PET agents for imaging of quinone reductase 2 and aromatase expression in breast Cancer.
- Monitoring the Longitudinal Intra-tumor Physiological Impulse Response to VEGFR2 Blockade in Breast Tumors Using DCE-CT.
- Facile synthesis of carbon-11-labeled cholesterol-based cationic lipids as new potential PET probes for imaging of gene delivery in Cancer.
- Design and synthesis of carbon-11-labeled dual aromatase-steroid sulfatase inhibitors as new potential PET agents for imaging of aromatase and steroid sulfatase expres...
- The role of vascular endothelial growth factor genetic variability in Cancer.
- Developing DCE-CT to quantify intra-tumor heterogeneity in Breast tumors with differing angiogenic phenotype.
- A phase II study of oral enzastaurin in patients with metastatic breast Cancer previously treated with an anthracycline and a taxane containing regimen.
- Incorporation of antiangiogenic therapies in the treatment of metastatic breast Cancer.
- Redefining the target again: chemotherapeutics as vascular disrupting agents?
- Clinical-translational approaches to the Nm23-H1 metastasis suppressor.
- Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast Cancer previously treated with an anthracycline...
- Development of new targeted therapies for breast Cancer.
- Antiangiogenic agents in breast Cancer.
- Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastat...
- Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate Cancer model.
- Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast Cancer.
- A physiologic imaging pilot study of breast Cancer treated with AZD2171.
- The potential and suitability of 2-methoxyestradiol in Cancer therapy.
- A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients wit...
- Angiogenesis of breast Cancer.
- Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast Cancer.
- Breast Cancer: the role of angiogenesis and antiangiogenic therapy.
- A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast Cancer.
- The role of ErbB inhibitors in trastuzumab resistance.
- A phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast Cancer.
- Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast Cancer.
- A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast Cancer.
- EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.
- NF-kappaB promotes breast Cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4.
- Thermoacoustic molecular imaging of Small animals.
- E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast Cancer.
- Angiogenesis and antiangiogenic therapy.
- Comparison of computational algorithms for the classification of liver Cancer using SELDI mass spectrometry: a case study.
- Synthesis of carbon-11 labeled celecoxib derivatives as new candidate PET radioligands for imaging of inflammation.
- Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compare...
- Synthesis of carbon-11-labeled tricyclic necroptosis inhibitors as new potential PET agents for imaging of tumor necrosis factor alpha (TNF-alpha).
- Synthesis of carbon-11-labeled 4-aryl-4H-chromens as new PET agents for imaging of apoptosis in Cancer.
- Synthesis of carbon-11-labeled tariquidar derivatives as new PET agents for imaging of breast Cancer resistance protein (ABCG2).
- Synthesis and in vitro biological evaluation of carbon-11-labeled quinoline derivatives as new candidate PET radioligands for cannabinoid CB2 receptor imaging.
- Incorporating the Oncotype DX breast Cancer assay into community practice: an expert Q&A and case study sampling.
- Simple synthesis of carbon-11 labeled styryl dyes as new potential PET RNA-specific, living cell imaging probes.
- Synthesis of new carbon-11 labeled naphthalene-sulfonamides for PET imaging of human CCR8.
- Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast Cancer.
- Synthesis of new carbon-11 labeled cyclofenil derivatives for PET imaging of breast Cancer estrogen receptors.
- Synthesis and preliminary biological evaluation of new carbon-11 labeled tetrahydroisoquinoline derivatives as SERM radioligands for PET imaging of ER expression in br...
- Synthesis of [11C]Iressa as a new potential PET Cancer imaging agent for epidermal growth factor receptor tyrosine kinase.
- Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET Cancer imaging agents.
- Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy Tissue.
- Synthesis of carbon-11 labeled sulfonanilide analogues as new potential PET agents for imaging of aromatase in breast Cancer.
- Synthesis of carbon-11 labeled biaryl 1,2,3,4-tetrahydroisoquinoline derivatives and conformationally flexible analogues as new potential PET glioma tumor imaging agents.
- Synthesis of radiolabeled stilbene derivatives as new potential PET probes for aryl hydrocarbon receptor in Cancers.
- Synthesis of carbon-11 labeled fluorinated 2-arylbenzothiazoles as novel potential PET Cancer imaging agents.
- Radiosynthesis of carbon-11-labeled camptothecin derivatives as potential positron emission tomography tracers for imaging of topoisomerase I in Cancers.
- Synthesis of [18F]SU11248, a new potential PET tracer for imaging Cancer tyrosine kinase.
- Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory.
- Synthesis of [18F]Xeloda as a novel potential PET radiotracer for imaging enzymes in Cancers.
- Can tumor angiogenesis be inhibited without resistance?
- Recent translational research: antiangiogenic therapy for breast Cancer - where do we stand?
- Synthesis, biodistribution and micro-PET imaging of a potential Cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-[[4-(6-fluorohex-1-ynyl)phenyl]sulfonylamino]-3...
- Comparative studies of potential Cancer biomarkers carbon-11 labeled MMP inhibitors (S)-2-(4''-[11C]methoxybiphenyl-4-sulfonylamino)-3-methylbutyric acid and N-hydroxy...
- Synthesis, biodistribution and micro-PET imaging of radiolabeled antimitotic agent T138067 analogues.
- Issues and challenges for antiangiogenic therapies.
- Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast Cancer imaging agents.
- [11C]Choline as a potential PET marker for imaging of breast Cancer athymic mice.
- Resistance in the anti-angiogenic era: nay-saying or a word of caution?
- [11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in Cancers.
- A brief intervention to minimize psychosexual morbidity in dyads coping with breast Cancer.
Schools
Johns Hopkins University School Of Medicine
Johns Hopkins Hospital
In University
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Anemia
- Bladder Cancer
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Indianapolis Monthly
Education
-
Indiana University School of Medicine -
Johns Hopkins University -
Johns Hopkins University School of Medicine
Drug Facts
| NPI NUMBER | 1649236043 | |
| NPPES Provider LastName | MILLER | |
| NPPES Provider FirstName | KATHY | |
| NPPES Provider ZIPCode | 462025112 | |
| NPPES Provider State | IN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 758.0 | |
| Distinct Opioid Count | 5.0 | |
| Opioid Claim Count | 109.0 | |
| Percent Opioid Claims | 14.38 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1649236043 |
| Last Name Of The Provider | MILLER |
| First Name Of The Provider | KATHY |
| View All |
Similar Doctors
|
Dr. Anuj K. Agarwala, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Danielle M. Doyle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jay A. Gaddy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. H S. Boswell Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kerry L. Blanchard, MD |
|
|
Dr. Robert P. Nelson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paolo B. Abada, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aparna C. Jotwani, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Costantine Albany, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Manan C. Patel, MD |
|
|
Dr. Richard A. Walgren, MD |
|
|
Dr. Elena G. Chiorean, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laura Tenner, MD |